Molina Healthcare IncNYSE: MOH

No material news in the last 48 hours.

Molina Healthcare hosted its Investor Day Conference on May 8, 2026, where management outlined long-term financial targets and detailed strategic and operational plans across Medicaid, Medicare, and Marketplace businesses. While management presented growth, AI and program initiatives, they warned the 2029 outlook faces substantial regulatory and cost risks. On May 11, shareholders approved governance and bylaw changes, and Truist raised its price target to $205 from $180. However, Barclays maintained a Sell rating on May 12, and a top executive made a notable insider stock sale on May 15. As of May 20, the stock traded in the $180-$188 range with concerns persisting about future Medicaid spending uncertainty. Overall sentiment remains cautious amid regulatory headwinds.

Molina Healthcare Unveils Long-Term Strategy at Investor Daytipranks.comMolina controls costs in Q1 but future Medicaid spending in doubthealthcaredive.comMolina Healthcare (MOH) Sets Ambitious Financial Goals for 2029gurufocus.com

Molina Healthcare held its Investor Day on May 8, 2026, outlining ambitious long-term targets including premiums near $48B by 2027 and revenue of $49.2B by 2029, with embedded earnings exceeding $11/share targeted for 2027-2029. CEO Joseph Zubretsky called 2026 a trough year for Medicaid industry margins. The stock rose 3.45% on May 12 to $191.58, but Zacks Research cut Q2 2026 EPS estimate to $1.27 from $1.68. Truist raised the price target to $205 from $180 on May 11, while Barclays maintained a Sell rating. Shareholders approved governance and bylaw changes on May 11, and a top executive made a notable insider sale on May 15.

Molina Healthcare Long-Term Strategy Investor Daytipranks.comMolina Healthcare 2029 Goalsgurufocus.comMolina Healthcare shares gain 3.45%ad-hoc-news.de

Molina Healthcare hosted its 2026 Investor Day on May 8, outlining long-term financial targets including premiums near $48 billion by 2027 and revenue of $49.2 billion by 2029, supported by growth, AI, and program initiatives. Management cautioned the 2029 outlook faces substantial regulatory and cost risks as 2026 remains a 'trough year' for Medicaid industry margins. Truist raised its price target to $205 from $180 on May 11, and Baird raised to $163 from $124 the same day, while Barclays maintained a Sell rating. The stock rose 3.45% on May 12 to $191.58, having rallied 26.64% over the prior month as investors look past the trough year. Shareholders approved governance and bylaw changes at the May 11 meeting, and several top executives executed notable insider stock sales in mid-May.

Molina Healthcare Unveils Long-Term Strategy at Investor Daytipranks.comMolina Healthcare (MOH) Sets Ambitious Financial Goals for 2029gurufocus.comMolina Healthcare (MOH) outlines 2026 Investor Day webcast and materialsstocktitan.net

Molina Healthcare stock declined 3.06% in the past 24 hours to $185.94, weighed down by two executive insider stock sales reported on May 12 and May 13, 2026. Truist raised its price target to $205 from $180 on May 11, 2026 following Molina May 8 Investor Day, where the company laid out long-term targets including premiums near $48B by 2027 and revenue of $49.2B by 2029. Shareholders also approved governance and bylaw changes including a 20% threshold for stockholders to call special meetings at the May 6 annual meeting. CEO Joseph Zubretsky has framed 2026 as a trough year for Medicaid industry margins with embedded earnings exceeding $11.00/share targeted for 2027-2029. Mixed signals as analyst optimism collides with insider selling.

Molina Healthcare stock (US60855R1005): Shares gain 3.45% to $191.58ad-hoc-news.deMolina Healthcare Shareholders Approve Governance and Bylaw Changestipranks.comMolina Healthcare (MOH) Sets Ambitious Financial Goals for 2029gurufocus.com

Molina Healthcare hosted its Investor Day Conference on May 8, 2026, outlining long-term financial updates with initiatives including AI deployment, capital allocation priorities, and program implementations. At the May 6, 2026 annual meeting, shareholders approved an amendment allowing stockholders holding at least 20% of voting power to call special meetings, with ten directors elected. Chief Legal Officer Jeff D. Barlow reported an open-market sale of 17,811 shares on May 11, 2026 at a VWAP of $186.12. Shares last closed at $191.97, up 28.0% over the past 30 days and 7.6% YTD, but down 38.4% over the past year. The most recent analyst rating is Buy with a $250 price target.

Molina Healthcare Unveils Long-Term Strategy at Investor Daytipranks.comMolina Healthcare 2026 Investor Day Materialsstocktitan.netMolina Healthcare CLO sells 17,811 sharesstocktitan.net

No material news in the last 48 hours.

Molina hosted its 2026 Investor Day on May 8, outlining a long-term strategic plan targeting adjusted EPS of $25 by 2029, up from at least $5 in 2026, driven by pretax margin expansion from less than 1% to about 2.5%. The stock fell 3.1% to $185.94 on May 8 as investors weighed the ambitious 2029 outlook against substantial regulatory and cost risks flagged by management. On May 6, shareholders approved governance amendments allowing 20% holders to call special meetings and elected ten directors. Truist raised its price target to $205 from $180 and Baird raised its target to $163 from $124 on May 11. The risk is execution of pretax margin expansion against Medicaid cost trend headwinds and rate-setting uncertainty.

Molina Healthcare Unveils Long-Term Strategy at Investor Daytipranks.comMolina Healthcare (MOH) Sets Ambitious Financial Goals for 2029gurufocus.comMolina Healthcare stock: Baird raises price target to $163ad-hoc-news.de

At its May 8, 2026 Investor Day, Molina Healthcare laid out long-term targets including adjusted EPS of $25 by 2029 while reaffirming FY26 adjusted EPS of at least $5. Truist raised its price target to $205 from $180 (Hold) and Baird lifted its target to $163 on May 11. Shareholders at the May 6 annual meeting approved a special-meeting threshold of 20% ownership, elected ten directors, and ratified EY as auditor. Bear case: shares fell 3.1% on Investor Day to ~$185.94 as the market questioned the credibility of out-year targets given near-term Medicaid redetermination headwinds, marketplace risk-adjustment volatility, and execution risk on the multi-year EPS bridge.

Molina Healthcare Unveils Long-Term Strategy at Investor Daytipranks.comMolina Healthcare Sets Ambitious Financial Goals for 2029gurufocus.com

Molina Healthcare held its Investor Day on May 8, 2026, where management laid out long-term financial targets including a $25 adjusted EPS goal by 2029. The company maintained FY2026 adjusted EPS guidance of at least $5. Shares fell 3.1% on May 8 to $185.94 as the company warned that its 2029 outlook faces substantial regulatory and cost risks. By May 10, the stock had fluctuated between $177.65 and $197.95. The company's strategic plan covers operational improvements and growth in Medicaid, Medicare and Marketplace segments. Director Francis Soistman filed initial Form 3 ownership of 500 shares on May 7. Recent analyst rating is Buy with $250 price target.

Molina Healthcare Investor Day - TipRankstipranks.comMOH 2029 Goals - Gurufocusgurufocus.comMOH Shares Fall 3.1% - Gurufocusgurufocus.com

Molina Healthcare held Investor Day conference on May 8, 2026. Q1 2026: GAAP EPS $0.27, adjusted EPS $2.35, served 5.0M members, premium revenue $10.2B. Company reaffirmed FY26 guidance: $42B premium revenue and adjusted earnings at least $5.00/diluted share. Medical cost trend modestly favorable. BofA double upgraded to Buy from Underperform. However, legal challenges: 16% stock drop triggered securities class action. Stock down 0.99% over 24 hrs from $192.70. Average analyst rating Hold with PT $157.15.

Molina Healthcare Q1 2026 Financial Resultsinvestors.molinahealthcare.comMolina Healthcare Investor Daytipranks.com

Molina Healthcare reported Q1 2026 GAAP income of $0.27 per share and adjusted income of $2.35 per share, with $10.2B premium revenue serving 5.0M members. Company reaffirmed FY2026 guidance of $42B premium revenue and adjusted EPS of $5.00+. However, company faces removal from S&P 500 index amid concerns over Medicaid margin compression and Obamacare cost pressures. BofA double-upgraded stock to Buy from Underperform.

Molina Healthcare Reports Q1 2026 Financial Resultsinvestors.molinahealthcare.comMolina Healthcare Stock Newsfinance.yahoo.com

Molina Healthcare reported Q1 2026 GAAP EPS of $0.27 and adjusted EPS of $2.35, with premium revenue of $10.2 billion and approximately 5.0 million members served. Company reaffirmed full-year 2026 guidance of $42 billion premium revenue and $5.00+ adjusted EPS. However, company faces significant challenges from Q4 2025 disappointment resulting in 28% stock drop. Strategic pivot involves exiting MAPD product by 2027 to focus on Duals products, with discussions ongoing for potential partner transfer. Investor Day scheduled for May 8, 2026.

Molina Healthcare Reports First Quarter 2026 Financial Resultsbusinesswire.comMolina Healthcare, Inc. Q1 2026 Earnings Call Summaryfinance.yahoo.comCNBC - MOH: Molina Healthcare Inccnbc.com